Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
30 nov. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Vacaville Establishes Fast Track Program for Biotechnology Projects
19 nov. 2020 11h15 HE
|
City of Vacaville
VACAVILLE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- The City of Vacaville, which last month unveiled plans for the next generation of development of its world-class biomanufacturing cluster, has...
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
13 oct. 2020 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
12 juin 2020 08h30 HE
|
Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
21 mai 2020 16h01 HE
|
Geron Corporation
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in...
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
12 mars 2020 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat,...
Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
26 févr. 2020 07h30 HE
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
09 déc. 2019 16h10 HE
|
Equillium
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events
06 nov. 2019 16h10 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as...
Geron to Announce Third Quarter Financial Results on November 6, 2019
31 oct. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2019 financial results after the market closes on...